B. Strober, “Bimekizumab maintenance of response through three years in patients with moderate to severe plaque psoriasis who responded at Week 16: Results from the BE BRIGHT open-label extension trial”, J of Skin, vol. 6, no. 6, p. s65, Nov. 2022.